Cape Investment Advisory Inc. Buys 92 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Cape Investment Advisory Inc. grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 1.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,269 shares of the medical research company’s stock after purchasing an additional 92 shares during the period. IQVIA makes up about 0.9% of Cape Investment Advisory Inc.’s portfolio, making the stock its 16th biggest position. Cape Investment Advisory Inc.’s holdings in IQVIA were worth $1,913,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Lazard Asset Management LLC increased its holdings in IQVIA by 2.9% during the 3rd quarter. Lazard Asset Management LLC now owns 2,889,263 shares of the medical research company’s stock worth $568,460,000 after purchasing an additional 80,189 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in IQVIA by 4.0% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,418,392 shares of the medical research company’s stock worth $532,070,000 after purchasing an additional 93,194 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in IQVIA by 3.4% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,325,198 shares of the medical research company’s stock worth $457,483,000 after purchasing an additional 77,422 shares during the period. Wellington Management Group LLP increased its holdings in IQVIA by 1.0% during the 3rd quarter. Wellington Management Group LLP now owns 1,816,266 shares of the medical research company’s stock worth $357,350,000 after purchasing an additional 17,139 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in IQVIA by 8.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,781,283 shares of the medical research company’s stock worth $350,467,000 after purchasing an additional 142,707 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Up 1.1 %

IQV stock traded up $2.51 on Friday, hitting $229.60. 751,380 shares of the company’s stock were exchanged, compared to its average volume of 893,862. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The firm has a 50 day moving average price of $237.13 and a two-hundred day moving average price of $228.73. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.88 and a current ratio of 0.88. The stock has a market cap of $41.83 billion, a P/E ratio of 31.37, a price-to-earnings-growth ratio of 2.09 and a beta of 1.52.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The company had revenue of $3.74 billion during the quarter, compared to analysts’ expectations of $3.69 billion. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other IQVIA news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Kevin C. Knightly sold 8,607 shares of the company’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the sale, the insider now owns 5,251 shares in the company, valued at $1,313,642.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the sale, the insider now directly owns 796,752 shares in the company, valued at $199,610,278.56. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have commented on IQV shares. Evercore ISI reduced their price objective on IQVIA from $275.00 to $250.00 and set an “outperform” rating on the stock in a report on Friday, May 3rd. BTIG Research began coverage on IQVIA in a report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price target on the stock. Truist Financial cut their price target on IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a report on Friday, May 3rd. Barclays lifted their price target on IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Finally, StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $257.57.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.